<html><head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head><body>
<span style="position:absolute; border: gray 1px solid; left:0px; top:50px; width:612px; height:792px;"></span>
<div style="position:absolute; top:50px;"><a name="1">Page 1</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:108px; width:497px; height:341px;"><span style="font-family: Arial,Bold; font-size:10px">Objective:</span><span style="font-family: Arial; font-size:10px"> Sweet taste receptors are stimulated by natural carbohydrates but also non-caloric natural 
<br>and artificial sweeteners, for example in energy-reduced softdrinks. Epidemiological studies suggest 
<br>associations between those dietary components and the development of metabolic diseases. The 
<br>reason for this relationship might be found in an unfavorable incretin release after ingestion of 
<br>artificially sweetened food. As a result from the SEGATROM study, we are conducting the ILIAS 
<br>project which aims to highlight possible selective properties of certain sweeteners and to assess the 
<br>real-life effects under prolonged stimulation.  
<br></span><span style="font-family: Arial,Bold; font-size:10px">Methods:</span><span style="font-family: Arial; font-size:10px"> First, we will focus on short-term effects of several artificial sweeteners with different 
<br>chemical structures. Additionally, a four-week stimulation with or without AS in a cross-over design is 
<br>scheduled. As in SEGATROM, oral stimulation tests will be conducted. Plasma levels for glucose, 
<br>insulin, GIP, GLP-1 and PYY will be assessed until 120 minutes after ingestion. 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Results: </span><span style="font-family: Arial; font-size:10px">The sweetener trials of the already completed SEGATROM study focussed primarily on 
<br>saccharin, an AS with both sweet and bitter taste. Preliminary results show significantly higher insulin, 
<br>GIP and GLP-1 levels under combined saccharin-glucose stimulation compared to glucose alone. 
<br>PYY levels remained similar. Saccharin alone did not reliably seem to stimulate incretin release. 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Conclusions/Outlook:</span><span style="font-family: Arial; font-size:10px"> The preliminary results from SEGATROM support the hypothesis, that food 
<br>containing AS (e.g. softdrinks) may facilitate metabolic derangements, possibly by disturbing a 
<br></span><span style="font-family: Arial; font-size:10px">beneficial incretin profile. As saccharin also stimulates bitter receptors, the role of sweet taste 
<br>receptors could not entirely be clarified by the SEGATROM study, thus requiring a broader 
<br>experimental design. We will investigate, if other sweeteners show similar or different effects, if co-
<br>administration of glucose is mandatory for the incretin release and if long-term effects on insulin 
<br>sensitivity can be detected after four weeks of continuous stimulation.  
<br></span><span style="font-family: Arial,Bold; font-size:10px">Protocol registration:</span><span style="font-family: Arial; font-size:10px"> NCT02219295 (clinicaltrials.gov) 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Funding Source:</span><span style="font-family: Arial; font-size:10px"> Federal Ministry of Education and Research  
<br></span><span style="font-family: Arial,Bold; font-size:10px"> 
<br></span><span style="font-family: Arial,Bold; font-size:11px"> 
<br>3.    PREVIEW: Prevention of diabetes through lifestyle intervention and population 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:78px; top:452px; width:466px; height:25px;"><span style="font-family: Arial,Bold; font-size:11px">studies in Europe and around the world - more than 2,000 volunteers randomized 
<br>to the 3-y intervention trial</span><span style="font-family: Arial,BoldItalic; font-size:11px">  
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:480px; width:501px; height:277px;"><span style="font-family: Arial,Bold; font-size:11px">(Jennie Brand-Miller) 
<br></span><span style="font-family: Arial,Italic; font-size:10px"> 
<br>Anne Raben</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, Mikael Fogelholm</span><span style="font-family: Arial,Italic; font-size:6px">2</span><span style="font-family: Arial,Italic; font-size:10px">, Thomas M Larsen</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, Mathijs Drummen</span><span style="font-family: Arial,Italic; font-size:6px">3</span><span style="font-family: Arial,Italic; font-size:10px">, Sally Poppitt</span><span style="font-family: Arial,Italic; font-size:6px">4</span><span style="font-family: Arial,Italic; font-size:10px">, J Alfredo 
<br>Martinez</span><span style="font-family: Arial,Italic; font-size:6px">5</span><span style="font-family: Arial,Italic; font-size:10px">, Ian Macdonald</span><span style="font-family: Arial,Italic; font-size:6px">6</span><span style="font-family: Arial,Italic; font-size:10px">, Svetoslav Handjiev</span><span style="font-family: Arial,Italic; font-size:6px">7</span><span style="font-family: Arial,Italic; font-size:10px">, Gareth Stratton</span><span style="font-family: Arial,Italic; font-size:6px">8</span><span style="font-family: Arial,Italic; font-size:10px">, Edith Feskens</span><span style="font-family: Arial,Italic; font-size:6px">9</span><span style="font-family: Arial,Italic; font-size:10px">, Tony Lam</span><span style="font-family: Arial,Italic; font-size:6px">10</span><span style="font-family: Arial,Italic; font-size:10px">, 
<br>Wolfgang Schlicht</span><span style="font-family: Arial,Italic; font-size:6px">11</span><span style="font-family: Arial,Italic; font-size:10px">, Jennie Brand-Miller*</span><span style="font-family: Arial,Italic; font-size:6px">12</span><span style="font-family: Arial,Italic; font-size:10px">, on behalf of the PREVIEW consortium 
<br></span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">Dep Nutrition, Exercise and Sports, University of Copenhagen, </span><span style="font-family: Arial,Italic; font-size:6px">2</span><span style="font-family: Arial,Italic; font-size:10px">Dep Food &amp; Environmental Sciences, 
<br>University of Helsinki, </span><span style="font-family: Arial,Italic; font-size:6px">3</span><span style="font-family: Arial,Italic; font-size:10px">Department of Human Biology, Maastricht University, </span><span style="font-family: Arial,Italic; font-size:6px">4</span><span style="font-family: Arial,Italic; font-size:10px">Human Nutrition 
<br>University, University of Auckland, </span><span style="font-family: Arial,Italic; font-size:6px">5</span><span style="font-family: Arial,Italic; font-size:10px">Department of Nutrition, University of Navarra, </span><span style="font-family: Arial,Italic; font-size:6px">6</span><span style="font-family: Arial,Italic; font-size:10px">School of Life 
<br>Sciences, University of Nottingham, </span><span style="font-family: Arial,Italic; font-size:6px">7</span><span style="font-family: Arial,Italic; font-size:10px">Department of Pharmacology and Toxicology, Medical University 
<br>Sofia, </span><span style="font-family: Arial,Italic; font-size:6px">8</span><span style="font-family: Arial,Italic; font-size:10px">College of Engineering, Swansea University, </span><span style="font-family: Arial,Italic; font-size:6px">9</span><span style="font-family: Arial,Italic; font-size:10px">Division of Human Nutrition, Wageningen 
<br>University, </span><span style="font-family: Arial,Italic; font-size:6px">10</span><span style="font-family: Arial,Italic; font-size:10px">Net Union, Lausanne, </span><span style="font-family: Arial,Italic; font-size:6px">11</span><span style="font-family: Arial,Italic; font-size:10px">Department of Sport &amp; Exercise Science, University of Stuttgart, 
<br></span><span style="font-family: Arial,Italic; font-size:6px">12</span><span style="font-family: Arial,Italic; font-size:10px">Charles Perkins Centre, University of Sydney 
<br></span><span style="font-family: Arial,Bold; font-size:10px"> 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Objective:</span><span style="font-family: Arial; font-size:10px"> PREVIEW is a 6-y EU project (2013-2018) under the FP7, KBBE programme. It involves 
<br>15 partners from Europe, Australia, Canada, and New Zealand. The primary goal is to identify the 
<br></span><span style="font-family: Arial; font-size:10px">most efficient lifestyle pattern for the prevention of type-2 diabetes (T2D) in a population of pre-
<br></span><span style="font-family: Arial; font-size:10px">diabetic overweight and obese individuals.  
<br></span><span style="font-family: Arial,Bold; font-size:10px">Methods: </span><span style="font-family: Arial; font-size:10px">The project comprises 2 main lines of evidence: a 3-y multicentre, 2x2 factorial, clinical, 
<br></span><span style="font-family: Arial; font-size:10px">randomized controlled trial (RCT) with up to 2,500 participants as well as large population studies in 
<br>about 170,000 individuals across all age groups. This presentation is focused on the RCT.  
<br>The impact of a high-protein, low-glycemic index diet vs a moderate protein, moderate-glycemic index 
<br>diet in combination with moderate or high intensity physical activity on the incidence of T2D and 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:781px; width:13px; height:24px;"><span style="font-family: ABCDEE+Calibri; font-size:11px">65 
<br> 
<br></span></div><span style="position:absolute; border: black 1px solid; left:456px; top:528px; width:3px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:47px; top:517px; width:0px; height:12px;"></span>
<div style="position:absolute; top:0px;">Page: <a href="#1">1</a></div>
</body></html>
